Error loading player: No playable sources found
4275
Gut Microbiome — Ally or Foe for Immune Checkpoint Inhibitors
Date
May 20, 2024
SOCIETY: AGA This session will explore the complex dynamics between the gut microbiome and immune checkpoint inhibitors, addressing whether specific microbes/metabolites enhance therapeutic outcomes acting as allies or present challenges as potential foes, impacting treatment efficacy and associated side effects.
Moderators
Mayo Clinic
Stanford University
Related Products
"Clinical Correlation Suggested": How to Handle Discrepancies Between Clinical and Pathologic Findings in Inflammatory GI Biopsies
SOCIETY: AGA This symposium focuses on frustrating scenarios where histopathologic examination of inflammatory gastrointestinal tract biopsies shows findings that do not match a patient's clinical scenario or provide a challenging differential diagnosis…
2024 AGA Guideline Highlights
SOCIETY: AGA AGA guidelines are among the most rigorously evidence-based and trusted guidelines in the field of GI and hepatology…
Irritable Bowel Syndrome in Inflammatory Bowel Disease: Boundaries Along a Continuum
SOCIETY: AGA IBS-like symptoms in patients with IBD are common, yet presenting a diagnostic and clinical challenge for patients and their providers…
